Clinical Trial Update: Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) [Phase 2]

View source ↗

Summary

A Phase 2 study of Everolimus (RAD001) in patients with recurrent glioblastoma multiforme was terminated, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Glioblastoma Multiforme | Phase 2 | Status: TERMINATED | Results posted: 2011-07-27